Item 8.01 Other Events.

Recently, the Company became aware that one of its contract manufacturers of MAT9001 suffered an explosion at its manufacturing facilities in Asia. None of the Company's key omega-3 intermediates stored at the facility were damaged or destroyed. The Company is in the process of determining the impact, if any, on the future manufacture of MAT9001 for use in the Company's planned Phase 3 AMPLIFY trial in patients with severe hypertriglyceridemia, which is currently scheduled to commence in the second half of 2021. The Company's head-to-head ENHANCE-IT trial of MAT9001 vs. Amarin's Vascepa® is not affected by this incident and is scheduled to report topline data in the first quarter of 2021.





Forward-Looking Statements

This Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the impact of the damage to one of the Company's contract manufacturers of MAT9001 and potential impact on the commencement of the Company's Phase 3 AMPLIFY trial, and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this Report on Form 8-K. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

-2-

© Edgar Online, source Glimpses